Genmab A-S

Затворен

1,349 0.63

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1331.5

Максимум

1356

Ключови измерители

By Trading Economics

Приходи

2.1B

3.8B

Продажби

901M

6.4B

P/E

Средно за сектора

10.638

57.333

EPS

60.121

Марж на печалбата

59.696

Служители

2,682

EBITDA

-297M

1.8B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-1.49% downside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-9.6B

81B

Предишно отваряне

1348.37

Предишно затваряне

1349

Genmab A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2025 г., 15:16 ч. UTC

Значими двигатели на пазара

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10.12.2024 г., 07:05 ч. UTC

Пазарно говорене

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Genmab A-S Прогноза

Ценова цел

By TipRanks

-1.49% надолу

12-месечна прогноза

Среден 2,493.35 DKK  -1.49%

Висок 3,320 DKK

Нисък 308.417 DKK

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Genmab A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

3

Купи

2

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.